Driving U.S. leadership in biopharmaceutical manufacturing

2025 U.S. Biopharma Workforce Partnership Conference

March 26-27, 2025 | Durham, NC

Antibody Manufacturing for Rapid Response

NIIMBL has published an action plan for increasing flexibility of antibody manufacturing for rapid response.

What we do

Advance biopharmaceutical manufacturing innovation

Collaborate on innovative manufacturing platforms and technologies that accelerate the development and manufacture of life-saving medicines and medical countermeasures, enhance national economic security, and support response to biothreats

Solve industry challenges

Help companies de-risk the adoption and implementation of new technologies and approaches for development and manufacturing

Develop the skilled workforce of the future

Strengthen the U.S. economy by cultivating a world-leading biopharmaceutical workforce that meets the industry’s needs through novel training and education programs

quotes

Together with our partners...we will ultimately enable life-saving and life-enhancing therapies to be brought to patients more quickly.

Udit Batra, President & CEO, Waters

Play video

Current solicitations

We achieve our mission through an RFx process that aims to advance technical and workforce development projects:

  • Request for Proposal (RFP): A solicitation sent to the entire NIIMBL community that is to result in funding of activities
  • Request for Information (RFI): An open invitation for organizations to share information; not directly associated with funding
  • Request for Applications (RFA): A focused solicitation to particular organizations to submit an application intended to result in funding of activities

See all opportunities
RFP 8.1
RFP 7.1
RFI 2024.1: Universal Connectivity
RFI 2024.2: Hybrid Model
RFA: Faculty Fellows

RFP 8.1

RFP 8.1 includes global health, technology development, and workforce development topics. It is open to current NIIMBL members and to new members by the close of the full proposal deadline.

Submission deadline is September 30, 2024.

Learn More

RFP 7.1

RFP 7.1 includes both technology development and workforce development topics, with a funding amount of up to $4 million. It is open to current NIIMBL members and to new members by the close of the full proposal deadline.

Project Call 7.1 closed on December 7, 2023. Submissions are now in review.

Learn more

RFI 2024.1: Universal Connectivity

RFI 2024.1 – Universal Connectivity for In-Process Analytics in Biopharmaceutical Manufacturing – aims to gather insights and ideas regarding the development of a Universal Connectivity System for at-line/inline analytical instrumentation. This initiative looks to support NIIMBL's Big Data program in biomanufacturing.

NIIMBL invites submissions from interested parties to share information on potential solutions for a Universal Connectivity System. This system is envisioned as an OT/IT core to facilitate seamless data integration and advanced analytics within biomanufacturing processes, thus enabling data-driven decision-making and process optimization.

Learn more about RFI 2024.1

RFI 2024.2: Hybrid Model

RFI 2024.2 – Hybrid Model Federated Learning – seeks innovative approaches that combine Federated Learning with hybrid models (combining Physics-Based and AI/ML data-driven methodologies) specifically tailored for biopharmaceutical manufacturing processes. This request aims to gather insights and concepts for achieving integration and operationalization of these models in a practical, industry-relevant context. By fostering collaboration among a wide range of stakeholders, we aim to enhance prediction accuracy of Hybrid Models for biopharmaceutical process predictions using Federated Learning and other Privacy Preserving Computing approaches. This initiative seeks to train a centralized model using community data while maintaining data privacy.

This RFI is a preliminary step to gauge interest and gather insights which may shape future studies or funding opportunities in Hybrid Model Federated Learning. This RFI is not a solicitation for funding proposals. We encourage contributions from all interested parties to become integral parts of this innovative endeavor.

Learn more about RFI 2024.2

RFA: Faculty Fellows

NIIMBL is pleased to announce the pilot of a faculty sabbatical in industry program. The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member (Tier 1 or Tier 2) or at NIIMBL’s Headquarters (NIIMBL HQ) in Delaware to support NIIMBL-led projects.

The NIIMBL Faculty Fellows program closes December 31, 2024.

Learn more

Current solicitations

We achieve our mission through an RFx process that aims to advance technical and workforce development projects:

  • Request for Proposal (RFP): A solicitation sent to the entire NIIMBL community that is to result in funding of activities
  • Request for Information (RFI): An open invitation for organizations to share information; not directly associated with funding
  • Request for Applications (RFA): A focused solicitation to particular organizations to submit an application intended to result in funding of activities

RFP 8.1arrow down

RFP 8.1

RFP 8.1 includes global health, technology development, and workforce development topics. It is open to current NIIMBL members and to new members by the close of the full proposal deadline.

Submission deadline is September 30, 2024.

Learn More

RFP 7.1 arrow down

RFP 7.1

RFP 7.1 includes both technology development and workforce development topics, with a funding amount of up to $4 million. It is open to current NIIMBL members and to new members by the close of the full proposal deadline.

Project Call 7.1 closed on December 7, 2023. Submissions are now in review.

Learn more

RFI 2024.1: Universal Connectivityarrow down

RFI 2024.1: Universal Connectivity

RFI 2024.1 – Universal Connectivity for In-Process Analytics in Biopharmaceutical Manufacturing – aims to gather insights and ideas regarding the development of a Universal Connectivity System for at-line/inline analytical instrumentation. This initiative looks to support NIIMBL's Big Data program in biomanufacturing.

NIIMBL invites submissions from interested parties to share information on potential solutions for a Universal Connectivity System. This system is envisioned as an OT/IT core to facilitate seamless data integration and advanced analytics within biomanufacturing processes, thus enabling data-driven decision-making and process optimization.

Learn more about RFI 2024.1

RFI 2024.2: Hybrid Modelarrow down

RFI 2024.2: Hybrid Model

RFI 2024.2 – Hybrid Model Federated Learning – seeks innovative approaches that combine Federated Learning with hybrid models (combining Physics-Based and AI/ML data-driven methodologies) specifically tailored for biopharmaceutical manufacturing processes. This request aims to gather insights and concepts for achieving integration and operationalization of these models in a practical, industry-relevant context. By fostering collaboration among a wide range of stakeholders, we aim to enhance prediction accuracy of Hybrid Models for biopharmaceutical process predictions using Federated Learning and other Privacy Preserving Computing approaches. This initiative seeks to train a centralized model using community data while maintaining data privacy.

This RFI is a preliminary step to gauge interest and gather insights which may shape future studies or funding opportunities in Hybrid Model Federated Learning. This RFI is not a solicitation for funding proposals. We encourage contributions from all interested parties to become integral parts of this innovative endeavor.

Learn more about RFI 2024.2

RFA: Faculty Fellowsarrow down

RFA: Faculty Fellows

NIIMBL is pleased to announce the pilot of a faculty sabbatical in industry program. The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member (Tier 1 or Tier 2) or at NIIMBL’s Headquarters (NIIMBL HQ) in Delaware to support NIIMBL-led projects.

The NIIMBL Faculty Fellows program closes December 31, 2024.

Learn more

See all opportunities

Who we are

Our members are stakeholders from across the biopharmaceutical manufacturing ecosystem, including large and small companies, academic institutions, and nonprofits.

Members have the opportunity to collectively revolutionize current biomanufacturing platforms, processes, and educational programs and share in the benefits of these transformative solutions.

No Data Found

June 30, 2023

Why NIIMBL

The NIIMBL ecosystem’s collaborative efforts to accelerate innovative manufacturing technologies help to:

  • Ensure a secure, integrated domestic supply chain
  • Enable lifesaving and life-enhancing therapies to reach patients more quickly
  • Strengthen biodefense
  • Cement the United States’ leadership in the global manufacturing industry
  • Increase the biopharmaceutical industry’s global competitiveness

About biopharmaceuticals and biomanufacturing

About biopharmaceuticals and biomanufacturing

Biopharmaceuticals are medicines and medical countermeasures that save, sustain, and improve lives. They:

  • are manufactured in, extracted from, or derived from biological sources and require complex manufacturing process.
  • treat and prevent some of the most prevalent and debilitating diseases affecting human health, including cancer, diabetes, autoimmune disorders, and bacterial and viral infections, making biopharma one of the most valuable and important business sectors in the United States.
  • play a crucial role in protecting the United States from health threats.
quotes

(NIIMBL) provides a structured space to experiment with approaches that will lead to our ability to rise to today's challenges and build a better future.

Mike Kress, Sr. Vice President Development Sciences and Clinical Supply,
Merck & Co., Inc.

Play video

Become a Member

We offer a variety of membership options that give you the flexibility to choose your organization’s level of engagement based on technology interests and priorities.